Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02914613 · ClinicalTrials.gov registry record · Phase 1
Safety and Exploratory Efficacy Study of SF0166 for the Treatment of Diabetic Macular Edema (DME)
A Phase 1 study of Diabetic Macular Edema, sponsored by OcuTerra Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 6
- Study locations
NCT02914613 is a Phase 1 study of Diabetic Macular Edema that has completed, run by OcuTerra Therapeutics. The registered enrollment target is 44 participants, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower). The trial reports 6 study locations across 4 states.
The verdict
NCT02914613, a Phase 1 study of Diabetic Macular Edema, has completed, sponsored by OcuTerra Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 6
- Study locations
Study Summary
The primary purpose of this study was to evaluate the safety and exploratory efficacy of SF0166 Topical Ophthalmic Solution in patients with Diabetic Macular Edema (DME).
Conditions Studied
Interventions
- DRUG SF0166 Topical Ophthalmic Solution
Study Locations (6)
California
- Retina-Vitreous Associates Medical Group - Beverly Hills
- United Medical Research Institute - Inglewood
- Martel Eye Medical Group - Rancho Cordova
Florida
- Center for Retina and Macular Disease - Winter Haven
Massachusetts
- Ophthalmic Consultants of Boston - Boston
Texas
- Retina Consultants of Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2016-08-24 |
| Est. Completion | 2017-05-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02914613
The ClinicalTrials.gov registry entry for NCT02914613 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower). The listed sponsor is OcuTerra Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Macular Edema appearing as the primary indexed condition, and to 1 intervention - of which SF0166 Topical Ophthalmic Solution is the first listed.
NCT02914613 reports 6 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02914613 about?
NCT02914613 is a clinical study titled "Safety and Exploratory Efficacy Study of SF0166 for the Treatment of Diabetic Macular Edema (DME)". The primary purpose of this study was to evaluate the safety and exploratory efficacy of SF0166 Topical Ophthalmic Solution in patients with Diabetic Macular Edema (DME).
What is the current status of trial NCT02914613?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2016-08-24. Estimated completion is 2017-05-16.
What conditions does trial NCT02914613 study?
This clinical trial studies the following conditions: Diabetic Macular Edema.
What interventions are being tested in trial NCT02914613?
The interventions under investigation include: SF0166 Topical Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT02914613?
This trial is sponsored by OcuTerra Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02914613 being conducted?
This trial has 6 study locations across California, Florida, Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of K9 in Subjects With Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema
RECRUITING · Phase 1
-
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
RECRUITING · Phase 1
-
Kamuvudine-9 (K9) in Diabetic Macular Edema
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.